A BILL 
To amend title XVIII of the Social Security Act to eliminate 
cost sharing for biosimilar biological products furnished 
under part B of the Medicare program. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Acting to Cancel 
4
Copays and Ensure Substantial Savings for Biosimilars 
5
Act of 2019’’ or the ‘‘ACCESS for Biosimilars Act of 
6
2019’’. 
7
21:21 Oct 07, 2019
H4597
2 
•HR 4597 IH
SEC. 2. ELIMINATING COST SHARING FOR BIOSIMILAR BIO-
1
LOGICAL 
PRODUCTS 
FURNISHED 
UNDER 
2
PART B OF THE MEDICARE PROGRAM. 
3
Section 1833 of the Social Security Act (42 U.S.C. 
4
1395l) is amended— 
5
(1) in subsection (a)(1)(S), by inserting ‘‘(or, in 
6
the case of such a biological that is a specified bio-
7
similar biological product (as defined in subsection 
8
(cc)) furnished during a year (beginning with 2020) 
9
to an individual who is a cost-sharing reduction eli-
10
gible individual (as defined in such subsection) with 
11
respect to such year, 100 percent)’’ after ‘‘80 per-
12
cent’’; and 
13
(2) by adding at the end the following new sub-
14
section: 
15
‘‘(cc) SPECIFIED BIOSIMILAR BIOLOGICAL PRODUCT 
16
REDUCED COST-SHARING PROVISIONS.— 
17
‘‘(1) DEFINITIONS.— 
18
‘‘(A) COST-SHARING REDUCTION ELIGIBLE 
19
INDIVIDUAL DEFINED.—For purposes of sub-
20
section (a)(1)(S) and with respect to a year, the 
21
term ‘cost-sharing reduction eligible individual’ 
22
means an individual who, as of January 1 of 
23
such year— 
24
‘‘(i) is enrolled under this part; and 
25
21:21 Oct 07, 2019
H4597
3 
•HR 4597 IH
‘‘(ii) does not have qualifying coverage 
1
(as defined in subparagraph (B)). 
2
‘‘(B) QUALIFYING COVERAGE.— 
3
‘‘(i) IN
GENERAL.—For purposes of 
4
subparagraph (A), the term ‘qualifying 
5
coverage’ means, with respect to an indi-
6
vidual, coverage— 
7
‘‘(I) under— 
8
‘‘(aa) a group health plan or 
9
health insurance coverage (as 
10
such terms are defined in section 
11
2791 of the Public Health Serv-
12
ice Act); 
13
‘‘(bb) a Federal health care 
14
program (as defined in section 
15
1128B(f)), other than the pro-
16
gram established under this title; 
17
‘‘(cc) the health insurance 
18
program under chapter 89 of 
19
title 5, United States Code; 
20
‘‘(dd) a medicare supple-
21
mental policy under section 1882; 
22
or 
23
‘‘(ee) an MA or MA–PD 
24
plan; and 
25
21:21 Oct 07, 2019
H4597
4 
•HR 4597 IH
‘‘(II) that meets— 
1
‘‘(aa) in the case of coverage 
2
described in any of items (aa) 
3
through (dd) of subclause (I), the 
4
condition described in clause (ii); 
5
and 
6
‘‘(bb) in the case of coverage 
7
described in item (ee) of sub-
8
clause (I), the condition described 
9
in clause (iii). 
10
‘‘(ii) 
CONDITION
FOR
COVERAGE 
11
OTHER
THAN
PART
C
COVERAGE.—For 
12
purposes of clause (i)(II)(aa), the condition 
13
described in this clause, with respect to an 
14
individual enrolled in coverage described in 
15
any of items (aa) through (dd) of clause 
16
(i)(I) during a year, is that such coverage 
17
provides for the payment of all cost shar-
18
ing owed by such individual under this 
19
part (or, if applicable, under an MA or 
20
MA–PD plan) with respect to a specified 
21
biosimilar biological product (as defined in 
22
subparagraph (C)) furnished under this 
23
part (or, if applicable, under an MA or 
24
MA–PD plan) during such year, not taking 
25
21:21 Oct 07, 2019
H4597
5 
•HR 4597 IH
into account the application of any deduct-
1
ible under such coverage. 
2
‘‘(iii) CONDITION
FOR
PART
C
COV-
3
ERAGE.—For 
purposes 
of 
clause 
4
(i)(II)(bb), the condition described in this 
5
clause, with respect to an individual en-
6
rolled in an MA or MA–PD plan during a 
7
year, is that such plan provides for no cost 
8
sharing for such individual with respect to 
9
a specified biological biosimilar product (as 
10
defined in subparagraph (C)) furnished 
11
under such plan during such year. 
12
‘‘(C) SPECIFIED
BIOSIMILAR
BIOLOGICAL 
13
PRODUCT.—For 
purposes 
of 
subsection 
14
(a)(1)(S), the term ‘specified biosimilar biologi-
15
cal product’ means a biosimilar biological prod-
16
uct (as defined in subsection (c)(6) of section 
17
1847A) for which the payment amount deter-
18
mined under subsection (b)(8) of such section 
19
for such product is less than the payment 
20
amount determined under subsection (b)(4) of 
21
such section for the reference biological product 
22
(as defined in subsection (c)(6) of such section). 
23
‘‘(2) DETERMINATIONS.—The Secretary shall 
24
establish a process— 
25
21:21 Oct 07, 2019
H4597
6 
•HR 4597 IH
‘‘(A) for determining whether an individual 
1
is a cost-sharing reduction eligible individual for 
2
a year; and 
3
‘‘(B) for notifying MA organizations of 
4
such a determination made with respect to an 
5
individual enrolled under an MA plan or MA– 
6
PD plan offered by such organization during 
7
such year.’’. 
8
Æ 
21:21 Oct 07, 2019
H4597
